NOVEL CARDIOPROTECTIVE PHARMACOLOGICAL STRATEGIES IN ISCHEMIA–REPERFUSION INJURY
Keywords:
type 2 diabetes mellitus; pharmacotherapy; SGLT2 inhibitors; GLP-1 receptor agonists; tirzepatide; cardiovascular risk; chronic kidney disease; precision treatment.Abstract
Type 2 diabetes mellitus (T2DM) pharmacotherapy has shifted from a glucose-centric model toward an integrated strategy that simultaneously targets glycemic control, body weight, atherosclerotic cardiovascular disease (ASCVD), heart failure, and chronic kidney disease (CKD). This structured evidence-based review evaluates contemporary drug classes and treatment strategies with emphasis on the 2026 American Diabetes Association (ADA) Standards of Care and major cardiovascular and kidney outcome trials. A focused literature synthesis was conducted using international guidelines, consensus reports, and landmark randomized controlled trials evaluating metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dual glucose-dependent insulinotropic polypeptide/GLP-1 receptor agonism, insulin, and adjunctive cardiorenal therapy. Current evidence supports phenotype-directed treatment rather than a uniform stepwise sequence. SGLT2 inhibitors are central when heart failure or CKD predominates, while GLP-1 RAs are prioritized in ASCVD and when substantial weight reduction is desired. Tirzepatide and high-efficacy GLP-1 RAs provide the greatest combined glucose- and weight-lowering effects among currently available noninsulin therapies. Cardiovascular outcome data now extend to oral semaglutide, while kidney outcome data from FLOW reinforce the role of semaglutide in T2DM with CKD. Finerenone adds kidney and cardiovascular protection in albuminuric CKD despite not being a glucose-lowering agent. Modern care therefore requires early combination therapy when appropriate, individualized sequencing, continuous reassessment, and attention to safety, tolerability, treatment burden, cost, and access. The therapeutic objective is no longer simply attainment of an HbA1c target; it is reduction of total cardiometabolic and kidney risk while preserving quality of life.
References
1.American Diabetes Association Professional Practice Committee for Diabetes. (2026). 9. Pharmacologic approaches to glycemic treatment: Standards of Care in Diabetes—2026. Diabetes Care, 49(Suppl. 1), S183-S215. https://doi.org/10.2337/dc26-S009
2.American Diabetes Association Professional Practice Committee for Diabetes. (2026). 10. Cardiovascular disease and risk management: Standards of Care in Diabetes—2026. Diabetes Care, 49(Suppl. 1), S216-S245. https://doi.org/10.2337/dc26-S010
3.Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., et al. (2022). Management of hyperglycemia in type 2 diabetes, 2022: A consensus report by the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 45(11), 2753-2786. https://doi.org/10.2337/dci22-0034
4.Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385, 503-515. https://doi.org/10.1056/NEJMoa2107519
5.SURPASS-CVOT Investigators. (2025). Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. New England Journal of Medicine, 393, 2409-2420. https://doi.org/10.1056/NEJMoa2505928
6.Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375, 311-322. https://doi.org/10.1056/NEJMoa1603827
7.Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375, 1834-1844. https://doi.org/10.1056/NEJMoa1607141
8.McGuire, D. K., et al. (2025). Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2501006
9.Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373, 2117-2128. https://doi.org/10.1056/NEJMoa1504720
10.Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019). Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 380, 347-357. https://doi.org/10.1056/NEJMoa1812389
11.Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., et al. (2019). Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New England Journal of Medicine, 380, 2295-2306. https://doi.org/10.1056/NEJMoa1811744
12.Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F. F., et al. (2020). Dapagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 383, 1436-1446. https://doi.org/10.1056/NEJMoa2024816
13.The EMPA-KIDNEY Collaborative Group. (2023). Empagliflozin in patients with chronic kidney disease. New England Journal of Medicine, 388, 117-127. https://doi.org/10.1056/NEJMoa2204233
14.Perkovic, V., Tuttle, K. R., Rossing, P., Mahaffey, K. W., Mann, J. F. E., Bakris, G., et al. (2024). Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine, 391, 109-121. https://doi.org/10.1056/NEJMoa2403347
15.Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., et al. (2020). Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. New England Journal of Medicine, 383, 2219-2229. https://doi.org/10.1056/NEJMoa2025845
